4-Ethylpyrogallol-trimethylether | 50564-22-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-Ethylpyrogallol-trimethylether
• 英文别名: 1-Ethyl-2,3,4-trimethoxybenzene
• CAS: 50564-22-2
• 化学式: C₁₁H₁₆O₃
• 分子量: 196.246
• InChiKey: IOKYJOMQPTVYKU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-Ethylpyrogallol-trimethylether 在 溴 作用下， 以 氯仿 为溶剂， 生成 5-Brom-1-ethyl-2,3,4-trimethoxybenzol
  参考文献：
  名称：

  Erdtman,H. et al., Acta Chemica Scandinavica (1947), 1970, vol. 24, p. 235 - 239

  摘要：

  DOI：
• 作为产物：
  描述：

  4-ethyl-pyrogallol 、 硫酸二甲酯 在 sodium hydroxide 作用下， 生成 4-Ethylpyrogallol-trimethylether
  参考文献：
  名称：

  Erdtman,H. et al., Acta Chemica Scandinavica (1947), 1970, vol. 24, p. 235 - 239

  摘要：

  DOI：

文献信息

• [EN] SELECTIVE 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS<br/>[FR] INHIBITEURS SÉLECTIFS DE LA 17-BÊTA-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE DE TYPE 1
  申请人：UNIV SAARLAND

  公开号：WO2012025638A1

  公开（公告）日：2012-03-01

  The invention relates to selective, non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 (17β-HSD1) inhibitors their production and use, especially for the treatment and/or prophylaxis of hormone-related diseases.

  这项发明涉及选择性的、非类固醇17β-羟基类固醇脱氢酶1型（17β-HSD1）抑制剂的生产和使用，特别用于治疗和/或预防激素相关疾病。
• BENZIMIDAZOLIUM DYES AND THEIR USE AS FLUORESCENT CHEMOSENSORS
  申请人：CHANG Young-Tae

  公开号：US20080160521A1

  公开（公告）日：2008-07-03

  The present invention is directed toward benzimidazolium dye compounds of formula (I) as follows: wherein, n is an integer from 2-10, m is an integer from 2-10, X 1 and X 2 are independently a halogen, Q is H or a resin, and R is (aromatic) o -(linker) p -with the linker being saturated or unsaturated C 1 -C5 hydrocarbons, each aromatic independently being a substituted or unsubstituted aromatic or heteroaromatic, o being 1 or 2, and p being 0 or 1. Methods of making and using these compounds are also disclosed.

  本发明涉及如下式（I）的苯并咪唑盐染料化合物：其中，n为2-10的整数，m为2-10的整数，X1和X2分别为卤素，Q为氢或树脂，R为（芳香基）o-(连接体)p-，其中连接体为饱和或不饱和的C1-C5烃链，每个芳香基独立地为取代或未取代的芳香基或杂芳香基，o为1或2，p为0或1。同时还公开了制备和使用这些化合物的方法。
• Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5
  申请人：Kamenecka M. Theodore

  公开号：US20070027321A1

  公开（公告）日：2007-02-01

  The present invention is directed to novel bipyridyl amine and ether compounds such as those of Formula (I): (I) (where R?1#191, R?2#191, R?3#191, X and Y are as defined herein) which are mGluR5 modulators useful in the treatment or prevention of diseases and conditions in which mGluR5 is involved, including but not limited to psychiatric and mood disorders such as schizophrenia, anxiety, depression, bipolar disorders, and panic, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders, such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal, obesity and other diseases. The invention is also directed to pharmaceutical compositions comprising these compounds. This invention further provides a method of treatment of these disorders and conditions by the administration of an effective amount of these novel bipyridyl amine and/or ether compounds and/or compositions containing these compounds.

  本发明涉及新型的联吡啶胺和醚化合物，例如公式(I)中的化合物：(I) (其中R?1#191，R?2#191，R?3#191，X和Y如本文所定义)，这些化合物是mGluR5调节剂，可用于治疗或预防涉及mGluR5的疾病和病况，包括但不限于精神和情绪障碍，如精神分裂症、焦虑、抑郁、双相障碍和惊恐，以及治疗疼痛、帕金森病、认知功能障碍、癫痫、昼夜节律和睡眠障碍，如倒班工作引起的睡眠障碍和时差反应、药物成瘾、药物滥用、戒断综合征、肥胖症和其他疾病。本发明还涉及包含这些化合物的药物组合物。本发明还提供了通过给予这些新型联吡啶胺和/或醚化合物和/或含有这些化合物的组合物的有效量来治疗这些障碍和病况的方法。
• Novel pyrrolidine compound and a process for preparing the same
  申请人：Moritani Yasunori

  公开号：US20070167440A1

  公开（公告）日：2007-07-19

  The present invention relates to a novel pyrrolidine compound, which has a potent antagonistic activity against central cannabinoid (CB1) receptor, having the formula [I]: wherein each of R 1 and R 2 is (A) optionally substituted aryl (or heteroaryl) group, or (B) both of the groups combine to form a group of the formula: one of R 3 and R 4 is hydrogen and another is hydrogen, hydroxyl, hydroxyalkyl, etc., or both of R 3 and R 4 combine to form oxo group, R 5 is hydrogen or alkyl, Y is single bond, oxygen atom or a group of the formula: —N(R 7 )—, R 6 is optionally substituted hydrocarbon group or optionally substituted cyclic group, R 7 is alkyl or alkyloxycarbonylalkyl, provided that R 6 is not 4-amino-5-chloro-2-methoxyphenyl group when Y is single bond and one of the R 3 and R 4 is hydrogen and another is hydroxymethyl, or a pharmaceutically acceptable salt thereof.

  本发明涉及一种新型吡咯烷化合物，其具有对中枢大麻素（CB1）受体的强烈拮抗活性，其化学式为[I]：其中，R1和R2中的每一个是（A）可选取的取代芳基（或杂环芳基）基团，或者（B）两个基团结合形成式的基团：R3和R4中的一个是氢，另一个是氢、羟基、羟基烷基等，或者R3和R4结合形成氧代基团，R5是氢或烷基，Y是单键、氧原子或式的基团：—N(R7)—，R6是可选取的取代的碳氢基团或可选取的取代的环状基团，R7是烷基或烷氧羰基烷基，但当Y为单键且R3和R4中的一个为氢，另一个为羟甲基时，R6不是4-氨基-5-氯-2-甲氧基苯基团，或其药学上可接受的盐。
• Piperidine derivatives having ccr3 antagonism
  申请人：Matsumoto Yoshiyuki

  公开号：US20070032525A1

  公开（公告）日：2007-02-08

  The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides compounds represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C 1 -C 6 alkyl adducts thereof, as well as pharmaceutical compositions comprising them as effective ingredients, which are useful for treatment or prevention of diseases associated with CCR3, such as asthma and allergic rhinitis.

  本发明提供了具有抑制CCR3配体结合到靶细胞CCR3的活性的低分子化合物，即CCR3拮抗剂。本发明还提供了由下式（I）表示的化合物，其药学上可接受的酸加合物或药学上可接受的C1-C6烷基加合物，以及包含它们作为有效成分的制药组合物，用于治疗或预防与CCR3相关的疾病，例如哮喘和过敏性鼻炎。